Kura Oncology (KURA) Stock Price, Quote, News & History | Benzinga

Kura Oncology Inc (KURA) Stock Price, Quote, News & History

KURANASDAQ

Trade with Public

Trade with Public

$12.40

0.514.29%

At close: Aug 21, 5:00 PM EST

$13.16

1.2710.68%

Pre-Market: 4:00 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$12.40

Volume / Avg.

2.23K / 1.78M

Day Range

- - -

52 Wk Range

7.36 - 12.90

Market Cap

$1.17B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

15.19%

Days to Cover

11.81

Recent Kura Oncology, Inc. News

Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday

US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.

Avi Kapoor

Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday

Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma Bravo and reporting strong Q2 results. Other top gainers include Omeros Corp (NASDAQ: OMER), CorMedix Inc (NASDAQ: CRMD), and Hyliion Holdings Corp (NYSE: HYLN).

Avi Kapoor

QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Dow futures down 100 points. QuickLogic (QUIK) falls after reporting worse-than-expected Q1 results. Other stocks also dip in pre-market trading.

Avi Kapoor

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.

Vandana Singh

Kura Scores A Big Win As FDA Approves Its New Leukemia Pill

Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-111.76M

Investing Cash Flow (TTM)

97.35M

Financing Cash Flow (TTM)

2.70M

Free Cash Flow (TTM)

-117.43M

Capital Expenditure (TTM)

-5.67M

Net Change in Cash (TTM)

-11.71M

Analyst Trends and Forecast

3

Mar

1

Apr

0

0

0

0

Jun

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$608.99M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

14.18

PB Ratio (TTM)

22.79

Earnings Yield % (TTM)

-27.17%

Earnings Yield % (FWD)

-27.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.54

Company Debt

Total Debt

$9.79M

LT Debt

$5.57M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$70.24M

Debt to Equity

0.50

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$12.40

Volume / Avg.

2.23K / 1.78M

Day Range

- - -

52 Wk Range

7.36 - 12.90

Market Cap

$1.17B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

15.19%

Days to Cover

11.81

About

Sector

Health Care

Industry

Biotechnology

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathway...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Kura Oncology (KURA) stock?

A

You can purchase shares of Kura Oncology (NASDAQ:KURA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kura Oncology (KURA) competitors?

A

Other companies in Kura Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Kura Oncology (KURA) stock?

A

Kura Oncology has a consensus price target of $24.13.

Q

What is the current price for Kura Oncology (KURA)?

A

The stock price for Kura Oncology (NASDAQ: KURA) is $13.16 last updated August 25, 2026 at 4:10 AM EDT.

Q

Does Kura Oncology (KURA) pay a dividend?

A

There are no upcoming dividends for Kura Oncology.

Q

When is Kura Oncology (NASDAQ:KURA) reporting earnings?

A

Kura Oncology does not have any upcoming earnings scheduled.

Q

Is Kura Oncology (KURA) going to split?

A

There is no upcoming split for Kura Oncology.

Q

What sector and industry does Kura Oncology (KURA) operate in?

A

Kura Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.